by Paul Stewart, Phillip Blanchette, Prakesh S. Shah, Xiang
Y. Ye, R. Gabriel Boldt, Ricardo Fernandes, Ted Vandenberg, Jacques Raphael
The Breast: Open
Access: Published: October 21, 2020
One year of adjuvant trastuzumab is considered the standard
treatment for patients with HER2 positive breast cancer. However, a shorter
duration of trastuzumab may be associated with reduced costs and side effects.
Results from randomized trials with diverse non-inferiority margins comparing
one year to a shorter duration of adjuvant trastuzumab are not consistent and
have not been systematically reviewed using a non-inferiority meta-analysis
approach.We conducted a systematic review and meta-analysis of randomized
trials to assess whether a shorter duration of adjuvant trastuzumab was
non-inferior to one year of treatment or not.
